Dr. Jeffrey D. Bleil This is Me

Education

 View all 63 references Web References

1. 1. MAVA: Calendar of Events: Venture Community Listings

   www.mava.org/calendar/communit - [Cached]

   Published on: 3/13/2008   Last Visited: 3/16/2008

   Confirmed speakers include: Aneesh Chopra, Secretary of Technology, Commonwealth of VA; Jeffrey D. Bleil, Ph.D., CTO, UTEK Corporation; Robert S. Capon, Co-founder & CEO, Adenosine Therapeutics, LLC; Mark Coburn, President, Virginia Tech Intellectual Properties; Ian Blasch, Director, Micron Ventures; Gerard Eldering, Founder and President, InnovateTech Ventures; Mark Frantz, General Partner, RedShift Ventures; Sean Gorman, CEO, Fortius One; Reenst Lesemann, Investment Professional, Tall Oaks Capital; Dr. Alan Merten, President, George Mason University; Kent Murphy, CEO, Luna Innovations; Don Rainey, General Partner, Grotech Capital Group; Gene Schleppenbach, Principal, Miles & Stockbridge P.C.; Tom Stroup, CEO, SquareLoop; Tom Weithman, Vice President of Entrepreneurship and Investment Services, CIT Gap Fund

2. 2. UTEK: Open Innovation

   www.utekcorp.com/files/managem - [Cached]

   Published on: 3/11/2008   Last Visited: 3/11/2008

   Jeffrey D. Bleil, Ph.D., Chief Scientific Officer
   
   Dr. Bleil has previously served as Research Fellow, Roche Institute of Molecular Biology, Assistant Professor and Principal Investigator at The Scripps Research Institute and founded and served as Director of Research at ZyGam, Inc. Dr. Bleil received his B.S. in Biological Chemistry from Lawrence University and a Ph.D. in Cell and Development Biology from Harvard Medical School. Dr. Bleil was a Postdoctoral Fellow at the MRC (Medical Research Council) Laboratory of Molecular Biology in Cambridge, England.

3. 3. 2004 Annual Meeting - Speaker Bios

   www.usa-canada.les.org/members - [Cached]

   Published on: 1/7/2005   Last Visited: 1/7/2005

   Jeffrey D. Bleil
   ...
   Jeffrey D. Bleil Jeffrey D. Bleil is the Chief Technology Officer of UTEK Corporation (AMEX: UTK). UTEK is a technology transfer company, the mission of which is to find, acquire, and transfer new University and Laboratory technologies to its corporate clients. Dr Bleil founded and served as Chief Technology Officer of ZyGam, Inc., a Biotechnology Company. Dr. Bleil received his B.S. in Biological Chemistry from Lawrence University, Appleton, and a Ph.D. in Cell and Development Biology from Harvard Medical School, Boston. Dr. Bleil was a Postdoctoral Fellow at The Medical Research Council Laboratory of Molecular Biology in Cambridge, England and an Assistant Professor and Principle Investigator in the Department of Molecular Biology at The Scripps Research Institute, La Jolla.